Back to Search
WELLS MESSERSMITH, MD
MD
Medical Oncology Physician
NPI: 1760431472IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
45719(CO)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
HARVARD MEDICAL SCHOOL
Class of 1998
Research & Publications (20)
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
PMID 19509264·Mol Cancer Ther·2009
7-preclinical
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
PMID 18379785·Cancer Chemother Pharmacol·2008
3-trial
Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?
PMID 17699842·Clin Cancer Res·2007
8-other
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
PMID 17084620·Eur J Cancer·2007
3-trial
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
PMID 16489083·Clin Cancer Res·2006
3-trial
Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis.
PMID 16319527·Cancer Biol Ther·2005
4-observational
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
PMID 15475439·Clin Cancer Res·2004
3-trial
Recent advances in the pharmacological treatment of colorectal cancer.
PMID 12605565·Expert Opin Investig Drugs·2003
6-review
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
PMID 19509160·Clin Cancer Res·2009
7-preclinical
Pharmacogenetic pathway analysis of docetaxel elimination.
PMID 18509327·Clin Pharmacol Ther·2009
4-observational
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
PMID 19380450·J Clin Oncol·2009
3-trial
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
PMID 19124802·J Clin Oncol·2009
6-review
No time to waste: decreasing patient wait times for chemotherapy administration using automated prioritization in an oncology pharmacy system.
PMID 18488295·Am J Manag Care·2008
8-other
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
PMID 18955447·J Clin Oncol·2008
3-trial
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
PMID 18765554·Clin Cancer Res·2008
3-trial
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
PMID 18757332·J Clin Oncol·2008
3-trial
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
PMID 18421048·J Clin Oncol·2008
3-trial
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer.
PMID 18413752·Cancer Res·2008
7-preclinical
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
PMID 18245131·Ann Oncol·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12605 E 16TH AVE
AURORA, CO 80045 - Phone
- (720) 848-0000
Quick Facts
- NPI
- 1760431472
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 28
- Publications
- 20
Are you this provider?
Claim Your Profile